MedTrace Logo

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

NCT06989957 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD).

To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet

Conditions

Interventions

DRUG

Psilocybin

Experimental Psilocybin (exact dosages not disclosed)

DRUG

Psilocybin

Comparator Psilocybin (exact dosages not disclosed)

DRUG

MDMA

Experimental MDMA (exact dosages not disclosed)

DRUG

MDMA

Comparator MDMA (exact dosages not disclosed)

Sponsors & Collaborators

Principal Investigators

  • Brandon Weiss, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2028-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06989957 on ClinicalTrials.gov